Mark Graves
Internal Medicine · Springfield, ILNPI 1285702308
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $872 of the $999 with a category attached, or 87.3%. 16 manufacturers reported payments, led by AstraZeneca at 31.0% of the total.
Across 68 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$310
- Amarin Pharma, Inc.$155
- Novo Nordisk$133
- Amgen$92
- AbbVie$64
- GSK$48
- plus $196 from 10 others
Across 15 payments — averaging $12,444 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$100K
- Novo Nordisk AS$44K
- AstraZeneca$24K
- Amarin Pharma, Inc.$19K
What the payments were for
- Food & beverage$87287%
- Education$12713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $310 |
| Amarin Pharma, Inc. | 21 | $155 |
| Novo Nordisk | 12 | $133 |
| Amgen | 6 | $92 |
| AbbVie | 4 | $64 |
| GSK | 3 | $48 |
| Boehringer Ingelheim | 3 | $35 |
| Merck | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Novartis | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$999 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $84,526 |
| OzempicSemaglutide | 41 | $58,564 |
| MounjaroTirzepatide | 18 | $26,062 |
| JardianceEmpagliflozin | 13 | $22,383 |
| FarxigaDapagliflozin Propanediol | 33 | $19,457 |
| Repatha SureclickEvolocumab | 22 | $17,509 |
| XareltoRivaroxaban | 12 | $15,255 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $15,140 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,144 |
| VascepaIcosapent Ethyl | 40 | $13,137 |
| BrilintaTicagrelor | 17 | $10,817 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 251 | $9,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,136 |
| OxycontinOxycodone Hcl | 20 | $6,990 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $133 | $58,56441 claims |
| GSKIncruse Ellipta, Breo Ellipta, Trelegy Ellipta | $48 | $37,42081 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $310 | $35,09171 claims |
| Lilly USA, LLCMounjaro | $12 | $26,06218 claims |
| Boehringer IngelheimJardiance | $35 | $22,38313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Springfield
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.